Cary Street Partners Asset Management’s Edwards Lifesciences EW Stock Holding History

Cary Street Partners Asset Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-240	Closed	-$19.9K	–	257
2023 Q1	$19.9K	Hold	240	–	–	﹤0.01%	301
2022 Q4	$17.9K	Hold	240	–	–	﹤0.01%	331
2022 Q3	$20K	Buy	+240	New	+$23.1K	﹤0.01%	283

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Cary Street Partners Asset Management's EW Position: Q2 2023 in Review

Cary Street Partners Asset Management sold out of Edwards Lifesciences (EW) in Q2 2023, closing a stake of 240 shares — an estimated $19.9K sold.

Cary Street Partners Asset Management first reported a position in EW in Q3 2022 and held it in 3 quarters. The position peaked at $20K in Q3 2022. 1,279 funds tracked by Wall St. Rank hold EW as of Q2 2023.

Cary Street Partners Asset Management reported no remaining Edwards Lifesciences position as of Q2 2023 after selling out during the quarter.
Cary Street Partners Asset Management sold 240 Edwards Lifesciences shares in Q2 2023, an estimated $19.9K.
Cary Street Partners Asset Management first reported a position in Edwards Lifesciences in Q3 2022 and held it in 3 quarters.
Cary Street Partners Asset Management's Edwards Lifesciences position peaked at $20K in Q3 2022.
1,279 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2023.

Based on Cary Street Partners Asset Management's 13F filing for Q2 2023, filed 10 Aug 2023.